GSK secures ex-Greater China rights to KRAS-EGFR therapy; $110M upfront
GSK won global licensing rights excluding Greater China to develop and commercialize a KRAS-EGFR antibody-targeted cancer therapy. Deal includes $110 million upfront plus up to $1.185 billion in milestones, with initial trials starting in H2 2026.